entertainment -WSS

entertainment

author：focus 2025-09-07 17:26:12 - browse：99

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Annovis Bio delivers candor, but not confidence, on Parkinson’s study

leisure time

WSS

A solution to the after

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

NIH study of ME/CFS points to clear biological hallmarks

FDA clears AI tool for detecting skin cancer

Medicare Advantage today, explained in one chart

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

entertainment

entertainment

focus

Affirmative action in medical school literally saved lives

Test for long Covid? Researchers find new clue in blood samples

The high cost of giving birth even with insurance

Parkinson’s finding may lead to tests and, someday, treatments

As demand for Covid shots wanes, Moderna seeks its next success

The Harvard botanist who searched for psychedelics in the Amazon

Medicare proposal to cover medical devices draws a mixed reaction

Alabama IVF ruling threatens families facing fatal genetic disease

Dobbs anniversary: the lost opportunity of abortion as health care

The tragedy of Johnson & Johnson’s Covid vaccine

hotspot

How digital therapeutics firms are pivoting after Pear's bankruptcy

The tragedy of Johnson & Johnson’s Covid vaccine

Obesity drugs seen as possible treatment for liver disease MASH

The surgeon had a dilemma only a Nazi medical text could resolve

Obesity drugs seen as possible treatment for liver disease MASH

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

focus

leisure time

knowledge

knowledge